About: Persistent SARS-CoV-2 replication in severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Persistent SARS-CoV-2 replication in severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Persistent SARS-CoV-2 replication in severe COVID-19
Creator	Delgado, Rafael Dolores, María Luczkowiak, Joanna Lasala Phd, Fátima Md, Folgueira Pérez-Rivilla, Alfredo
Source	MedRxiv
abstract	Background: The diagnosis of SARS-CoV-2 infection is based on viral RNA detection by real-time RT-PCR (rRT-PCR) in respiratory samples. This detection can remain positive for weeks without implying virus viability. Methods: We have performed cell culture to assess viral replication in 106 respiratory samples rRT-PCR positive for SARS-CoV-2 from 105 patients with COVID-19. Fifty were samples from 50 patients with mild forms of COVID-19 who did not require hospital admission. Fifty-six samples were obtained from 55 hospitalized patients with severe pneumonia. Samples were obtained at different time points covering the time from clinical diagnosis to the follow up during hospital care. Results: In 49 samples (49/106, 46.2%) a cytopathic effect (CPE) was detected in cell culture. Our study demonstrates that while in patients with mild COVID-19, viral viability is maintained in fact up to 10 days in patients with severe COVID-19 the virus can remain viable for up to 32 days after the onset of symptoms. Patients with severe COVID-19 as compared with mild cases, presented infective virus in a significantly higher proportion in samples with moderate or low viral load (Ct value > 26): 22/46 (47.8%) versus 7/38 (18.4%), (p <0.01), respectively. Conclusions: Persistent SARS-CoV-2 replication could be demonstrated in severe COVID-19 cases for periods up to 32 days after the onset of symptoms and even at high Ct values. COVID-19 severity is a more determining factor for viral viability than the time elapsed since the onset of symptoms or the Ct value obtained in the RT-PCR assay.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.10.20127837
has license	medrxiv
sha1sum (hex)	96e5c5c0a56a2dd342e46dabe380f4cfd2ea5aef
schema:url	https://doi.org/10.1101/2020.06.10.20127837
resource representing a document's title	Persistent SARS-CoV-2 replication in severe COVID-19
resource representing a document's body	covid:96e5c5c0a56a2dd342e46dabe380f4cfd2ea5aef#body_text
is schema:about of	named entity 'samples' named entity 'This' named entity 'viral replication' named entity 'severe' named entity 'POINTS' named entity 'VIRAL RNA' named entity 'ASSESS' named entity 'TIME' named entity 'FORMS' named entity 'FIFTY' named entity 'WEEKS' named entity 'implying' named entity 'admission' named entity 'Samples' named entity 'hospital' named entity 'positive' named entity 'hospital' named entity 'infection' named entity 'positive' named entity 'The' named entity 'viral replication' named entity 'SARS-CoV-2' named entity 'real-time RT-PCR' named entity 'virus' named entity 'diagnostic method' named entity 'symptom' named entity 'Open Access' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'June 12' named entity 'COVID' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'assay' named entity 'CC-BY 4.0 International license' named entity 'antivirals' named entity 'COVID-19' named entity 'bilateral pneumonia' named entity 'infectivity' named entity 'Hospital Universitario 12 de Octubre' named entity 'Madrid' named entity 'serum' named entity 'SARS-CoV-2' named entity 'rRT-PCR' named entity 'viral shedding' named entity 'Berlin' named entity 'SARS-CoV-2' named entity 'cell culture' named entity 'titer' named entity 'amphotericin' named entity 'CO2' named entity 'preprint' named entity 'preprint' named entity 'teaching hospital' named entity 'statistically significant' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'medRxiv' named entity 'medRxiv' named entity 'infectivity' named entity 'CC-BY 4.0 International license' named entity 'preprint' named entity 'follow-up' named entity 'steroids' named entity 'lung tissue' named entity 'preprint' named entity 'fetal bovine serum' named entity 'San Diego' named entity 'FITC' named entity 'Spain' named entity 'immunofluorescence' named entity 'preprint' named entity 'COVID' named entity 'medRxiv' named entity 'rRT-PCR' named entity 'SARS-CoV-2 virus' named entity 'Italy' named entity 'RNA' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software